Finding Genius Podcast
Rewiring Recovery: Advancing Nervous System Repair With NervGen’s Mike Kelly
Apr 8, 2025
Mike Kelly, President and CEO of NervGen, brings over 30 years of pharmaceutical expertise to the table. He discusses groundbreaking advancements in nervous system repair, particularly regarding spinal cord injuries. The conversation dives into clinical trials for their promising drug candidate, NVG-291, and how new protocols might change the landscape of recovery. Mike also highlights the importance of biomarker analysis in indicating breakthroughs, and shares insights on the journey to FDA approval, emphasizing the impact on real-world treatment.
17:13
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- NervGen's lead drug candidate, NVG-291, targets inhibiting molecules that prevent nerve regeneration, potentially addressing a critical medical need for spinal cord injury patients.
- The ongoing clinical trial evaluates the efficacy of NVG-291 in different time frames post-injury, aiming for significant improvements in nerve signaling and motor functionality.
Deep dives
The Role of NerveGen in Nervous System Repair
NerveGen focuses on repairing the nervous system, particularly in cases of spinal cord injury. The company’s lead product candidate, MBG291, aims to inhibit the molecules that prevent nerve regeneration in the central nervous system, which was discovered by the late Dr. Jerry Silver. The technology could potentially address a significant unmet medical need by allowing nerves to regenerate. Current clinical trials are underway to assess the efficacy of MBG291 in patients who have suffered spinal cord injuries, both in chronic and subacute stages.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
